CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law
Bleichmar Fonti & Auld LLP is investigating Capricor Therapeutics for potential securities fraud related to statements concerning Deramiocel and the integrity of its clinical data. The investigation follows a 64.5% stock drop on July 27, 2026, after FDA briefing documents raised concerns about post-hoc changes to the statistical analysis plan for the primary endpoint.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.